2 results
Approved WMOCompleted
- to evaluate the FVIIa activity PK of 2 CSL689 dose levels in subjects with congenital FVII deficiency- to determine the PK characteristics of FVIIa activity of CSL689- to evaluate the safety and tolerability of intravenous administration of CSL689
Approved WMOCompleted
In patients with symptomatic New York Heart Association (NYHA) Class II/III/IV dilated cardiomyopathy (DCM) in which mutations in the gene encoding the lamin A/C protein (LMNA) have been implicated:Primary Objective:* NYHA Class II/III patients only…